• Patients using other MAO inhibitors (eg, selegiline hydrochloride, rasagiline mesilate)


  • Patients using pethidine hydrochloride-containing products, tramadol hydrochloride-containing products, or tapentadol hydrochloride.


  • Patients using tricyclic antidepressants (eg, amitriptyline hydrochloride, amoxapine, imipramine hydrochloride, clomipramine hydrochloride, dosulepin hydrochloride, trimipramine maleate, nortriptyline hydrochloride, lofepramine hydrochloride), tetracyclic antidepressants (eg, maprotiline hydrochloride, mianserin hydrochloride, setiptiline maleate), selective serotonin reuptake inhibitors (eg, fluvoxamine maleate, paroxetine hydrochloride hydrate, sertraline hydrochloride, escitalopram oxalate), serotonin–noradrenaline reuptake inhibitors (eg, milnacipran hydrochloride, duloxetine hydrochloride, venlafaxine hydrochloride), selective noradrenaline reuptake inhibitor (atomoxetine hydrochloride), noradrenergic and serotonergic antidepressant (mirtazapine), or central nervous system stimulants (eg, methylphenidate hydrochloride, lisdexamfetamine mesilate)


  • Patients with severe hepatic impairment (Child-Pugh C)


  • Patients with a history of hypersensitivity to any of the ingredients of this drug


  • Pregnant women or women suspected of being pregnant